Stockscreener 앱 받기
22.44
1.13%
0.25
시간 외 거래:
22.44
전일 마감가:
$22.19
열려 있는:
$21.78
하루 거래량:
1.03M
Relative Volume:
1.60
시가총액:
$1.01B
수익:
$681.75M
순이익/손실:
$70.47M
주가수익비율:
15.48
EPS:
1.45
순현금흐름:
$173.19M
1주 성능:
+5.06%
1개월 성능:
-9.66%
6개월 성능:
-15.16%
1년 성능:
+36.41%
1일 변동 폭
$21.20
$22.61
1주일 범위
$20.70
$22.74
52주 변동 폭
$16.00
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
650-242-8052
주소
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
PCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.44 | 997.06M | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 업그레이드 | Truist | Hold → Buy |
| 2025-01-30 | 업그레이드 | Truist | Sell → Hold |
| 2024-08-13 | 다운그레이드 | Truist | Buy → Sell |
| 2024-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2024-08-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 재개 | JP Morgan | Overweight |
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Pacira BioSciences (PCRX) Partners with AmacaThera to Develop Lo - GuruFocus
Pacira signs exclusive license with AmacaThera for long-acting analgesic for postsurgical pain relief - MarketScreener
Pacira Signs Exclusive License With AmacaThera For Long-Acting Analgesic For Postsurgical Pain Relief - TradingView
Pacira BioSciences Expands Pipeline with Exclusive License for AMT-143, a Novel Non-Opioid Analgesic for Postsurgical Pain Control - Quiver Quantitative
Pacira BioSciences licenses novel long-acting pain control formulation By Investing.com - Investing.com Australia
Pacira BioSciences licenses novel long-acting pain control formulation - Investing.com
AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform - Yahoo Finance
Pacira BioSciences Inc. recovery potential after sell offJuly 2025 Update & AI Driven Price Predictions - newser.com
Using data tools to time your Pacira BioSciences Inc. exitPortfolio Update Summary & Stepwise Entry and Exit Trade Signals - newser.com
Should I hold or sell Pacira BioSciences Inc. stock in 2025Weekly Trading Summary & Verified Momentum Stock Watchlist - newser.com
Real time social sentiment graph for Pacira BioSciences Inc.Earnings Recap Report & Advanced Swing Trade Entry Alerts - newser.com
Is Pacira BioSciences Inc. stock supported by strong fundamentals2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Why Pacira BioSciences Inc. (82P) stock could outperform next year2025 Breakouts & Breakdowns & Reliable Volume Spike Trade Alerts - newser.com
Will Pacira BioSciences Inc. (82P) stock rise with strong economy2025 Retail Activity & Long-Term Safe Investment Plans - newser.com
Is Pacira BioSciences Inc. stock poised for growthJuly 2025 Big Picture & Accurate Intraday Trading Signals - newser.com
Will Pacira BioSciences Inc. stock keep outperforming rivals2025 Bull vs Bear & Technical Pattern Based Buy Signals - newser.com
How Pacira BioSciences Inc. stock valuations compare to rivals2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
How to integrate Pacira BioSciences Inc. into portfolio analysis toolsTrade Entry Report & Free Verified High Yield Trade Plans - newser.com
What is the fair value estimate for Pacira BioSciences Inc. (82P) stock in 2025Risk Management & Daily Profit Focused Screening - newser.com
Pacira BioSciences Inc. stock retracement – recovery analysisInflation Watch & Real-Time Buy Signal Alerts - newser.com
Can a trend reversal in Pacira BioSciences Inc. lead to recoveryTrade Volume Summary & Weekly Top Gainers Alerts - newser.com
Building trade automation scripts for Pacira BioSciences Inc.Quarterly Portfolio Review & Risk Controlled Daily Plans - newser.com
How Pacira BioSciences Inc. stock trades before earningsMarket Movement Recap & Accurate Entry and Exit Point Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
2025-11-02 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo Finance
Pacira BioSciences, Inc. (PCRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Chart based analysis of Pacira BioSciences Inc. trendsTrade Volume Summary & Growth Focused Stock Reports - newser.com
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 - markets.businessinsider.com
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.60%
0.45%
자본화:
|
볼륨(24시간):